UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~September~~December 2928, ~~2010~~2009

Commission file number: 333-152398

Niusule ~~Biotech~~Bio-pharmaceutical Corp.

(Exact Name of Registrant as Specified in Its Charter)

Nevada		2834		26-2401986
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		IRS I.D.

2533 North Carson Street, Carson City, NV		89706-0242
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number: 775-887-4880

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item 3~~Item1.0301 Entry ~~Material~~into ~~Modification~~a toMaterial ~~Rights~~Definitive ~~of Security Holders~~Agreement.

OnBased ~~July~~on 2,the ~~2010,~~Share ~~effective~~Exchange ~~September~~Agreement 30(the "Agreement") made and entered into on December 28, ~~2010~~2009, ~~the~~between ~~Registrant~~Niusule ~~filed~~Biotech ~~Amended~~Corp., ~~and~~a ~~Restated Articles~~Nevada ofcorporation ~~Incorporation~~("Buyer") and onMr. Peizhu ~~July 29~~Fan, ~~2010~~a ~~filed~~citizen aof ~~further~~People’s ~~Correction Amendment~~Republic ~~thereto~~of China ("Seller"), ~~which~~currently ~~are~~a Director ~~file~~of asBuyer, ~~exhibits~~the toParties ~~this~~reached ~~Form~~on ~~8-K~~December ~~and~~28, ~~should~~2009 bea supplemental ~~referred~~agreement to inthe ~~their~~terms ~~entirety~~of ~~with~~the ~~respect~~Share toExchange ~~these~~Agreement ~~matters~~(the “Supplemental Agreement”).

~~The~~On March ~~rights~~1, of2010, Niusule gave notice (the ~~holders~~“Notice”) ofthat ~~Common~~has ~~Stock~~been ~~are~~passed ~~affected~~by incompany’s 2009 ~~that~~annual shareholders’ meeting to repurchase the ~~Board~~common stock of the company ~~Directors~~sold ~~may~~from ~~now~~March ~~take~~15-31, ~~the~~2010 ~~following~~at ~~actions~~USD0.5 ~~without~~per ~~shareholder~~share. ~~vote~~Specific orrepurchase ~~holders~~procedures ofand ~~shares~~other ofmatters ~~Common Stock~~ are ~~affected~~set byforth in the ~~following:~~Notice.

~~Authorized~~The ~~Shares:~~Supplemental Agreement and the Notice are filed as an exhibit to this report and should be referred to in their entirety for a complete description thereof.

~~The~~Item ~~aggregate number of shares, which the corporation shall have authority to issue, shall consist of Common Stock, $0~~2.~~001~~01 ~~par~~Completion ~~value; 100,000, and Preferred Stock, $0.001 par value; 10,000,000 shares authorized. The Common and/or Preferred Stock~~ of ~~the~~Acquisition ~~Company may be issued from time to time without prior approval by the stockholders. The Common and/~~or ~~Preferred~~Disposition ~~Stock may be issued for such consideration as may be fixed from time to time by the Board~~ of ~~Directors~~Assets. The Board of Directors may issue such share of Common and/or Preferred Stock in one or more series, with such voting powers, designations, preferences and rights or qualifications, limitations or restrictions thereof as shall be stated in the resolution or resolutions.

~~Preemptive~~See ~~Rights~~disclosure ~~and~~under ~~Assessment~~Item 1.01 of ~~Shares:~~this Report, which is incorporated by reference in this Item 3.02.

~~Holders~~Item of3.02. ~~Common~~Unregistered ~~Stock~~Sales ~~or Preferred Stock~~ of ~~the~~Equity corporation shall not have any preference, preemptive right or right of subscription to acquire shares of the corporation authorized, issued, or sold, or to be authorized, issued or sold, or to any obligations or shares authorized or issued or to be authorized or issued, and convertible into shares of the corporation, nor to any right of subscription thereto, other than to the extent, if any, the Board of Directors in its sole discretion, may determine from time to timeSecurities.

~~Power~~See disclosure under Item 1.10 of ~~Directors~~this Report, which is incorporated by reference in this Item 3.02.

In furtherance, and not in limitation of those powers conferred by statute, the Board of Directors is expressly authorized:

(a) Subject to the By-Laws, if any, adopted by the shareholders, to make, alter or repeal the By-Laws of the corporation;

(b) To authorize and caused to be executed mortgages and liens, with or without limitations as to amount, upon the real and personal property of the corporation;

(c) To authorize the guaranty by the corporation of the securities, evidences of indebtedness and obligations of other persons, corporations or business entities;

(d) To set apart out of any funds of the corporation available for dividends a reserve or reserves for any proper purpose and to abolish any such reserve;

(e) By resolution adopted by the majority of the whole board, to designate one or more committees to consist of one or more directors of the of the corporation, which, to the extent provided on the resolution or in the By-Laws of the corporation, shall have and may exercise the powers of the Board of Directors in the management of the affairs of the corporation, and may authorize the seal of the corporation to be affixed to alt papers which may require it. Such committee or committees shall have name and names as may be stated in the By-Laws of the corporation or as may be determined from time to time by resolution adopted by the Board of Directors.

All the corporate powers of the corporation shall be exercised by the Board of Directors except as otherwise herein or in the By-Laws or by law.

Section 8 - Other Events

On July 2, 2010, effective September 30, 2010, the Registrant filed Amended and Restated Articles of Incorporation and on July 29, 2010 filed a further Correction Amendment thereto, which are file as exhibits to this Form 8-K and should be referred to in their entirety with respect to these matters.

Exhibits

10.1 ~~Original~~Supplemental ~~Nevada Filing~~Agreement

10.2 ~~Corrected~~ ~~Nevada Filing~~Notice

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

	NIUSULE BIOTECH CORP.
	NIUSULE BIO-PHARMACEUTICAL CORP.
Date: September 29, 2010	By:	/s/ Qinghua Hu
Date: November 12, 2010	By:	/s/ Qinghua Hu
		Qinghua Hu,
		Chairman

Filing Compare · Niusule Bio-pharmaceutical Corp.